台股分析全新上線!超值優惠立即查看!

Ligand pharmaceuticals inc

美股醫療保健藥物生技

LGND 投資分析

看多重點:

  • 價值≥4
  • 股利≥2
  • 價值 3 分

    基本面表現一般,但獲利仍相對平穩,屬於較穩健的公司

  • 股利 1 分

    沒有發放股利紀錄

分析結論

價值面評分中等,已經有部位可以持續持有,若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

LGND 近期報酬表現

-1.80%

Ligand pharmaceuticals inc

-0.72%

同產業平均

-0.20%

S&P500

與 LGND 同產業的標的表現

  • VCYT Veracyte inc
    價值 3 分趨勢 4 分波段 2 分籌碼 3 分股利 1 分市值 1.9B
    查看更多

LGND 公司資訊

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. Its products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and others. Kyprolis is formulated with its Captisol technology. Teriparatide Injection is a drug indicated for use including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. It also owns berdazimer gel and all the assets related to the NITRICIL technology platform, and rights to Sitavig program.

LGND 股價